Alyeska Investment Group’s Cogent Biosciences COGT Stock Holding History

Alyeska Investment Group’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.6M	Buy	274,849 +24,849	+10%	+$869K	0.03%	420
2026 Q1	$9.62M	Sell	250,000 -243,934	-49%	-$9.01M	0.03%	403
2025 Q4	$17.5M	Buy	493,934 +393,934	+394%	+$11.1M	0.05%	330
2025 Q3	$1.44M	Buy	+100,000	New	+$1.18M	﹤0.01%	524
2024 Q1	–	Sell	-50,000	Closed	-$294K	–	485
2023 Q4	$294K	Hold	50,000	–	–	﹤0.01%	461
2023 Q3	$488K	Hold	50,000	–	–	﹤0.01%	451
2023 Q2	$592K	Buy	+50,000	New	+$574K	﹤0.01%	487

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Alyeska Investment Group's COGT Position: Q2 2026 in Review

Alyeska Investment Group increased its Cogent Biosciences (COGT) stake by 9.9% in Q2 2026, buying an estimated $869K and bringing the position to 274,849 shares worth $10.6M. The position accounts for 0.03% of the portfolio, ranked #420.

Alyeska Investment Group first reported a position in COGT in Q2 2023 and has held it in 7 quarters since. The position peaked at $17.5M in Q4 2025. 322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Alyeska Investment Group held 274,849 shares of Cogent Biosciences worth $10.6M as of Q2 2026.
Alyeska Investment Group bought 24,849 Cogent Biosciences shares in Q2 2026, an estimated $869K.
Cogent Biosciences made up 0.03% of Alyeska Investment Group's portfolio in Q2 2026, its #420 holding.
Alyeska Investment Group first reported a position in Cogent Biosciences in Q2 2023 and has held it in 7 quarters since.
Alyeska Investment Group's Cogent Biosciences position peaked at $17.5M in Q4 2025.
322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.